Delcath to present phase 2 trial results at ESMO congress

Delcath Systems (DCTH) is demonstrating robust financial performance, highlighted by strong Q2 2025 results that surpassed analyst expectations (EPS $0.07, revenue $24.2M) and a 491% LTM revenue growth, supported by a healthy balance sheet. The company is set to present key CHOPIN Phase 2 trial data for its CHEMOSAT system combined with immunotherapy for metastatic uveal melanoma at ESMO on October 18, 2025, while also initiating a global Phase 2 trial for its HEPZATO treatment in liver-dominant metastatic colorectal cancer, signaling significant pipeline advancement and potential market expansion. Analysts currently project substantial upside from the current share price.

Analysis

Delcath Systems (DCTH) is exhibiting robust financial health and significant operational momentum. The company reported impressive second-quarter 2025 results, with earnings per share of $0.07 and revenue of $24.2 million, surpassing analyst projections of $0.03 and $22.78 million, respectively. This performance is supported by exceptional trailing-twelve-month revenue growth of 491% and a strong gross profit margin of 85.86%. The balance sheet appears solid, characterized by a cash position exceeding debt and a high current ratio of 10.88x, indicating strong liquidity. A key near-term catalyst is the scheduled presentation of the CHOPIN Phase 2 trial results at the ESMO Annual Congress on October 18, 2025, which will detail the performance of its CHEMOSAT system in combination with immunotherapy for metastatic uveal melanoma. Furthermore, Delcath is strategically expanding its clinical pipeline by initiating a global Phase 2 trial for its FDA-approved HEPZATO treatment in liver-dominant metastatic colorectal cancer, a potentially larger market. This combination of strong current financial execution, a near-term clinical data catalyst, and long-term pipeline expansion underpins analyst price targets ranging from $21 to $31, suggesting significant upside from the current price of approximately $11.56.

Key Decisions for Investors

• Investors should closely monitor the CHOPIN Phase 2 trial data presentation at ESMO on October 18, 2025, as positive results could act as a significant near-term valuation catalyst.
• Given the substantial beat on both Q2 2025 revenue and EPS, alongside a 491% LTM revenue growth rate, investors may view the current valuation as compelling relative to the company's demonstrated execution and analyst price targets.
• The initiation of a Phase 2 trial in metastatic colorectal cancer represents a key long-term growth driver, but positions should account for the clinical and regulatory risks associated with pipeline expansion into new indications.